Who is running the most trials right now

If you want to know where the sponsor-side jobs and the CRO contracts are, follow the trials. The registry names the sponsor on every study, and while it will not tell you which CRO does the work, the lead sponsor is reliable. Rank the big pharma names by how many trials they are actively recruiting and you get a directional map of who is spending on clinical research right now.

The directional ranking

Recruiting trials by sponsor, from the public registry. Read these as approximate: the sponsor search matches name variants and collaborator listings, so treat the ranking as directional rather than a precise league table.

• AstraZeneca: about 375
• Merck: about 310
• Novartis: about 270
• Pfizer: about 240
• Bristol-Myers Squibb: about 200
• Eli Lilly: about 190
• AbbVie: about 170
• Janssen (Johnson & Johnson): about 170
• Sanofi: about 150
• Regeneron: about 140
• GlaxoSmithKline: about 130
• Roche (Hoffmann-La Roche): about 120
• Takeda: about 120
• Novo Nordisk: about 100

The names at the top are the ones with the most active clinical programs, which is a rough proxy for where hiring demand and outsourced CRO work concentrate. AstraZeneca, Merck, Novartis, and Pfizer lead a tier of their own.

Why active count is the useful number

Total historical trials tell you which company has been big for decades. Active recruiting trials tell you who is spending now, which is what matters if you are job hunting or deciding where to aim a sponsor-side move. A sponsor recruiting hundreds of trials is running clinical operations at scale, contracting CROs heavily, and hiring or backfilling against real current work. A sponsor whose active count has thinned is the opposite, regardless of its historical size.

The list also tells CRO staff something. The sponsors at the top are the ones handing the most work to the CROs, so a CRA or programmer at a CRO is very likely working an AstraZeneca, Merck, or Pfizer program whether the badge says so or not. Knowing which sponsors are busiest is knowing where your own work ultimately comes from.

The honest caveats

Two of them. First, the sponsor search is fuzzy, so the exact numbers are approximate and the ordering within a tier can shift. Second, and more important, active trial count is a proxy for demand, not a guarantee of hiring. A sponsor can run many trials while freezing headcount and pushing the work to CROs, or cut internal staff while outsourcing more. The trial count tells you where the work is, not where the open roles are posted this week.

What the registry cannot tell you

The registry ranks sponsors by trials. It cannot tell you which of them pays well, treats clinical staff decently, or is quietly cutting even as it recruits studies. Those are the things that actually decide where you want to work, and they exist only in the experience of people who work there. The salary survey and this community are where that lives. If you work sponsor side, add your datapoint. The registry shows who is busiest. Only insiders show who is worth joining.